Meridian Bioscience Exhibits Curian Immunofluorescent Testing Platform at ECCMID 2022
Posted on 25 Apr 2022
Meridian Bioscience, Inc. (Cincinnati, OH, USA) exhibited its best-in-class immunoassay, molecular, and blood chemistry diagnostic solutions focused on gastrointestinal, neonatal, pediatrics, and respiratory conditions at ECCMID 2022.
Among its diagnostic solutions featured at ECCMID 2022 was Meridian’s Curian immunofluorescent testing platform focused in gastrointestinal testing that is packaged in a small footprint to improve hospital operational efficiencies. Curian boasts a simple workflow and clean sample handling to provide a rapid result that eliminates the subjectivity of traditional rapid immunoassay diagnostic tests. Curian provides healthcare systems a rapid fluorescent immunoassay diagnostic solution with a standardized, simplified workflow that eliminates subjectivity. Laboratories can eliminate workflow burdens and achieve optimal efficiency while delivering top-of-the-line patient care. The platform can be easily integrated into any laboratory or healthcare system.
Meridian also demonstrated different assays for gastrointestinal disease testing that can be run on the Curian immunofluorescent testing platform, including the Curian HpSA and Curian Campy assays. The Curian platform and Curian HpSA assay are designed to quickly detect Helicobacter pylori antigens in human stool using immunofluorescent technology. Curian HpSA is intended to aid in the diagnosis of H. pylori infection and to demonstrate loss of H. pylori antigen following treatment (i.e., confirmation of eradication). The immunofluorescent technology of the Curian platform provides an objective, rapid H. pylori result with state-of-the-art clinical sensitivity, specificity, and a lower limit of detection than traditional rapid immunoassay testing. Combined with LIS connectivity, the Curian solution helps to eliminate subjectivity by reducing user variability related to interpreting and reporting visually based test results.
The FDA-cleared Curian Campy assay is a rapid, qualitative fluorescent immunoassay for the detection of a Campylobacter-specific antigen including C. jejuni, C. coli, C. upsaliensis, and C. lari in human fecal specimens. The assay is designed for use on the Curian immunofluorescent testing platform assay and features an easy workflow and produces objective results in about 20 minutes. Curian Campy offers clinicians accurate and timely results to deliver appropriate care for patients infected with campylobacteriosis.
Related Links:
Meridian Bioscience, Inc.
